CompletedPHASE2, PHASE3NCT02370251

Compassionate Use of Omegaven in Children

Studying Biliary atresia and associated disorders

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Oklahoma
Principal Investigator: Kimberly D Ernst, MD, MSMI
The University of Oklahoma, Department of Pediatrics
Intervention: Omegaven(drug)
Enrollment: 63 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2019

Study locations (1)

OU Children's Hospital, Oklahoma City, Oklahoma, United States

Collaborators

OU Medical Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02370251 on ClinicalTrials.gov

Other trials for Biliary atresia and associated disorders

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06708572
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
National Liver Institute, Egypt

See all trials for Biliary atresia and associated disorders →

← Back to all trials